Laprophan Group Acquires Controlling Stake in Rivopharm

June 17, 2026

Laprophan Group completed the acquisition of a controlling stake in Rivopharm, a Switzerland-based specialty pharmaceutical company focused on specialty medicines, dossier development, and complex formulations. The deal strengthens Laprophan’s European footprint and supports its ambition to build an international pharmaceutical platform across Europe, Africa, the Middle East, and selected global markets.

Buyers
Laprophan Group, Europhan
Targets
Rivopharm
Platforms
Europhan
Industry
Pharmaceuticals
Location
Ticino, Switzerland
Transaction Type
Buyout

Explore More

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.